News Releases

Date Title and Summary View
Apr 17, 2002
Former U.S. Surgeon General David Satcher Elected to Johnson & Johnson Board
Former U.S. Surgeon General David Satcher Elected to Johnson & Johnson Board NEW BRUNSWICK, N.J., April 17 /PRNewswire/ -- David Satcher, M.D., Ph.D., former Surgeon General of the United States, was elected to the Board of Directors of Johnson & Johnson, the world's leading health care
Apr 16, 2002
Johnson & Johnson Reports First Quarter Increases in Sales and Net Earnings
Johnson & Johnson Reports First Quarter Increases in Sales and Net Earnings New Brunswick, NJ (April 16, 2002) -- Johnson & Johnson today announced sales of $8.7 billion and net earnings of $1.8 billion for the first quarter of 2002, increases of 11.3% and 18.2%, respectively, over first quarter
Apr 15, 2002
Cordis' CYPHER(TM) Sirolimus-eluting Stent Receives CE Mark Approval
Cordis' CYPHER(TM) Sirolimus-eluting Stent Receives CE Mark Approval BRUSSELS, Belgium, April 15 /PRNewswire-FirstCall/ -- Cordis Corporation, a Johnson & Johnson company, today reported its new CYPHER(TM) Sirolimus- eluting Stent received CE Mark approval in Europe for treatment of de novo
Apr 11, 2002
In the First Published Report of its Kind, Data Suggest Reminyl(R) Effectively Treats Dementia in Patients with Cerebrovascular Disease
LONDON, April 11 /PRNewswire/ -- Results of a study published today in The Lancet suggest that Reminyl® (galantamine hydrobromide), the newest approved treatment for mild to moderate Alzheimer's disease, also is effective in treating a broad range of dementia symptoms in individuals with
Apr 09, 2002
Johnson & Johnson to Host Analyst Meeting on First-Quarter Earnings
NEW BRUNSWICK, N.J., April 9 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ - news ) will release first-quarter earnings and sponsor a meeting for financial analysts at 8:30 a.m. on Tuesday, April 16, 2002. The meeting will be hosted by Christine Poon, Worldwide Chairman, Pharmaceuticals
Apr 08, 2002
Multimedia Available: It's No Laughing Matter: New Survey Reveals the Emotional Impact of Incontinence
(BUSINESS WIRE)-- In the new Multi-sponsor Surveys' Gallup study of women with stress urinary incontinence (SUI), 70 percent of those surveyed said they worry about coughing, sneezing and even laughing in public for fear of having an accident. You can reach the story directly by going to
Apr 05, 2002
Improvement Reported in Rheumatoid Arthritis Symptoms 48 Hours After Initial Treatment With REMICADE & (infliximab)
Improvement Reported in Rheumatoid Arthritis Symptoms 48 Hours After Initial Treatment With REMICADE & (infliximab) MALVERN, Pa., April 5 /PRNewswire/ -- According to a new study published in the April issue of The Journal of Rheumatology, patients with rheumatoid arthritis (RA) may experience
Apr 03, 2002
Survivor Attends Houston Seminar to Encourage Others To Survive and Succeed With Rheumatoid Arthritis
Survivor Attends Houston Seminar to Encourage Others To Survive and Succeed With Rheumatoid Arthritis HOUSTON, April 3 /PRNewswire/ -- Tina Wesson has proven that she is the ultimate survivor on the hit reality-TV series: "Survivor: The Australian Outback." However, six weeks in the Outback was not
Mar 23, 2002
New Jersey, Maryland and Virginia High School Teams Ally to Win 2002 Johnson & Johnson/FIRST Mid-Atlantic Regional Robotics Competition
New Jersey, Maryland and Virginia High School Teams Ally to Win 2002 Johnson & Johnson/FIRST Mid-Atlantic Regional Robotics Competition NEW BRUNSWICK, N.J., March 23 /PRNewswire-FirstCall/ -- Demonstrating superior skill and collaborative strategy, New Jersey, Maryland and Virginia high school
Mar 22, 2002
Johnson & Johnson to Acquire Tibotec-Virco
Johnson & Johnson to Acquire Tibotec-Virco NEW BRUNSWICK, N.J., March 22 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced it has signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV, a privately-held biopharmaceutical company focused on developing anti-viral
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.